Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JUNIOR PITTACK

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1023053931
CMS profile
698
Location
HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,109.27

212 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,951.77 207
Education $157.50 5

By paying entity

PY2019 · entire year · sorted by reported total

Page 5 of 5; records 201–212 of 212 matching records. This page contains 12 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JUNIOR PITTACK

NPI 1023053931 · CMS profile ID 698

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 5; records 201–212 of 212 matching records. This page contains 12 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023053931?year=2019&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JUNIOR PITTACK, NPI 1023053931, CMS profile ID 698. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–212 of 212 matching records. This page contains 12 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023053931?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JUNIOR PITTACK, NPI 1023053931, CMS profile ID 698. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 5; records 201–212 of 212 matching records. This page contains 12 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023053931?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JUNIOR PITTACK, NPI 1023053931, CMS profile ID 698, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 5; records 201–212 of 212 matching records. This page contains 12 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1023053931?year=2019&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

212 matching records · $3,109.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 212 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–212 of 212.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan Inc. $4.6601/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670955719 CMS
Sunovion Pharmaceuticals Inc. $17.1901/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688204035 CMS
Otsuka America Pharmaceutical, Inc. $22.3601/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687459137 CMS
Shire North American Group Inc $17.1301/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637896813 CMS
Sunovion Pharmaceuticals Inc. $7.3101/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688204033 CMS
Lundbeck LLC $24.0001/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684331423 CMS
Allergan Inc. $3.7001/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670955715 CMS
Neurocrine Biosciences, Inc. $15.2801/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693156611 CMS
Sunovion Pharmaceuticals Inc. $6.5201/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688204031 CMS
Allergan Inc. $14.4401/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670955711 CMS
Otsuka America Pharmaceutical, Inc. $17.6301/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687459135 CMS
Sunovion Pharmaceuticals Inc. $6.6501/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688204029 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,109.27 212
PY2020 $2,078.63 114
PY2021 $660.95 32
PY2022 $1,117.42 25
PY2023 $1,860.40 29
PY2024 $1,060.84 18
PY2025 $1,169.48 31

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,139,619.42 313
PY2024 Principal investigator $497,683.04 151
PY2023 Principal investigator $9,788.02 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

313 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alkermes, Inc. $1,981.80 12/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208615591
Principal investigator 1 Alkermes, Inc. $3,005.78 12/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208616277
Principal investigator 1 Alkermes, Inc. $3,025.35 12/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208620998
Principal investigator 1 Alkermes, Inc. $3,025.35 12/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208623432
Principal investigator 1 Alkermes, Inc. $3,005.78 12/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208625403
Principal investigator 1 Alkermes, Inc. $2,910.60 12/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208614815
Principal investigator 1 Alkermes, Inc. $2,910.60 12/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208615053
Principal investigator 1 Alkermes, Inc. $2,632.50 12/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208619673
Principal investigator 1 Alkermes, Inc. $2,189.70 12/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208621014
Principal investigator 1 Alkermes, Inc. $2,870.10 12/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208623176
Principal investigator 1 Alkermes, Inc. $2,189.70 12/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208624076
Principal investigator 1 Alkermes, Inc. $2,870.10 12/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208624947
Principal investigator 1 Alkermes, Inc. $2,910.60 12/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208626278
Principal investigator 1 Alkermes, Inc. $1,981.80 11/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208613261
Principal investigator 1 Alkermes, Inc. $2,263.95 11/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208614805
Principal investigator 1 Alkermes, Inc. $1,981.80 11/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208615837
Principal investigator 1 Alkermes, Inc. $3,025.35 11/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208616689
Principal investigator 1 Alkermes, Inc. $2,835.00 11/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208618473
Principal investigator 1 Alkermes, Inc. $4,166.10 11/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208620588
Principal investigator 1 Alkermes, Inc. $4,094.55 11/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208622697
Principal investigator 1 Alkermes, Inc. $2,835.00 11/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208623434
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,056.00 11/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242367073
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,941.00 11/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242367075
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,786.00 11/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242367077
Principal investigator 1 Alkermes, Inc. $1,556.89 11/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208613461
Principal investigator 1 Alkermes, Inc. $2,910.60 11/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208613463
Principal investigator 1 Alkermes, Inc. $3,199.50 11/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208613898
Principal investigator 1 Alkermes, Inc. $1,000.01 11/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208615397
Principal investigator 1 Alkermes, Inc. $1,000.01 11/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208616053
Principal investigator 1 Alkermes, Inc. $1,556.89 11/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208616275
Principal investigator 1 Alkermes, Inc. $2,910.60 11/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208617971
Principal investigator 1 Alkermes, Inc. $2,984.85 11/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208618207
Principal investigator 1 Alkermes, Inc. $1,556.89 11/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208619423
Principal investigator 1 Alkermes, Inc. $1,000.01 11/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208623168
Principal investigator 1 Alkermes, Inc. $1,000.01 11/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208623426
Principal investigator 1 Alkermes, Inc. $1,556.89 11/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208623428
Principal investigator 1 Alkermes, Inc. $2,984.85 11/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208623430
Principal investigator 1 Alkermes, Inc. $2,632.50 11/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208624520
Principal investigator 1 Alkermes, Inc. $2,870.10 11/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208624522
Principal investigator 1 Alkermes, Inc. $2,632.50 11/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208625884
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,000.00 11/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242366155
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,000.00 11/19/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242366157
Principal investigator 1 Alkermes, Inc. $1,347.50 11/13/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208615455
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,000.00 11/05/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242365819
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,000.00 11/05/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242365821
Principal investigator 1 Alkermes, Inc. $2,835.00 10/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208617529
Principal investigator 1 Alkermes, Inc. $2,263.95 10/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208622691
Principal investigator 1 Alkermes, Inc. $4,166.10 10/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208622950
Principal investigator 1 Alkermes, Inc. $2,835.00 10/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208623640
Principal investigator 1 Alkermes, Inc. $4,094.55 10/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208623642
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,023.00 10/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242364175
Principal investigator 1 Alkermes, Inc. $2,984.85 10/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208617375
Principal investigator 1 Alkermes, Inc. $3,800.25 10/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208618227
Principal investigator 1 Alkermes, Inc. $2,632.50 10/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208618229
Principal investigator 1 Alkermes, Inc. $2,984.85 10/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208620600
Principal investigator 1 Alkermes, Inc. $2,984.85 10/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208621424
Principal investigator 1 Alkermes, Inc. $2,984.85 10/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208621865
Principal investigator 1 Alkermes, Inc. $2,870.10 10/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208623836
Principal investigator 1 Alkermes, Inc. $2,870.10 10/17/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208625177
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,354.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242361106
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,682.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242361108
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $105.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242361110
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $54.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242361112
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $103.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242361114
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,017.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242361116
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,125.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242361118
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,211.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242361120
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $105.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242361122
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,422.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242361124
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,704.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242361126
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,023.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242361128
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,588.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242361130
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,918.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242361132
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,681.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242361891
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $77.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242361893
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $54.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242361895
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $77.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242361897
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $54.00 10/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242361899
Principal investigator 1 Alkermes, Inc. $1,000.00 09/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208616599
Principal investigator 1 Alkermes, Inc. $2,835.00 09/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208617017
Principal investigator 1 Alkermes, Inc. $2,835.00 09/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208617435
Principal investigator 1 Alkermes, Inc. $1,500.00 09/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208620229
Principal investigator 1 Alkermes, Inc. $2,835.00 09/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208620461
Principal investigator 1 Alkermes, Inc. $3,005.78 09/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208623716
Principal investigator 1 Alkermes, Inc. $1,981.80 09/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208625277
Principal investigator 1 Alkermes, Inc. $3,469.50 09/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208625523
Principal investigator 1 Alkermes, Inc. $3,800.25 09/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208612943
Principal investigator 1 Alkermes, Inc. $2,870.10 09/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208613381
Principal investigator 1 Alkermes, Inc. $2,189.70 09/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208614693
Principal investigator 1 Alkermes, Inc. $2,870.10 09/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208618607
Principal investigator 1 Alkermes, Inc. $2,632.50 09/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208618831
Principal investigator 1 Alkermes, Inc. $2,870.10 09/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208619053
Principal investigator 1 Alkermes, Inc. $2,984.85 09/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208620694
Principal investigator 1 Alkermes, Inc. $2,984.85 09/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208620900
Principal investigator 1 Alkermes, Inc. $3,199.50 09/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208622799
Principal investigator 1 Alkermes, Inc. $3,800.25 09/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208623056
Principal investigator 1 Alkermes, Inc. $3,800.25 09/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208624180
Principal investigator 1 Alkermes, Inc. $3,199.50 09/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208626576
Principal investigator 1 Alkermes, Inc. $3,199.50 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208613371
Principal investigator 1 Alkermes, Inc. $2,189.70 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208613553
Principal investigator 1 Alkermes, Inc. $1,981.80 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208614236
Principal investigator 1 Alkermes, Inc. $2,632.50 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208616785
Principal investigator 1 Alkermes, Inc. $2,835.00 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208617229
Principal investigator 1 Alkermes, Inc. $3,005.78 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208618089
Principal investigator 1 Alkermes, Inc. $2,870.10 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208618333
Principal investigator 1 Alkermes, Inc. $2,870.10 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208618815
Principal investigator 1 Alkermes, Inc. $2,870.10 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208619529
Principal investigator 1 Alkermes, Inc. $2,632.50 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208620467
Principal investigator 1 Alkermes, Inc. $2,632.50 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208620469
Principal investigator 1 Alkermes, Inc. $2,835.00 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208621712
Principal investigator 1 Alkermes, Inc. $2,910.60 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208622165
Principal investigator 1 Alkermes, Inc. $3,025.35 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208624412
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,541.00 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242357496
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,714.00 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242357498
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,714.00 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242357500
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,920.00 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242357502
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,975.00 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242357504
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $54.00 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242357506
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $135.00 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242357508
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $103.00 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242357510
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $103.00 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242357512
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $54.00 08/20/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242357514
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,681.00 08/14/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242357096
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,975.00 08/04/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242355826
Principal investigator 1 Alkermes, Inc. $2,870.10 07/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208614020
Principal investigator 1 Alkermes, Inc. $1,981.80 07/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208614903
Principal investigator 1 Alkermes, Inc. $2,870.10 07/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208616781
Principal investigator 1 Alkermes, Inc. $2,870.10 07/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208618329
Principal investigator 1 Alkermes, Inc. $2,835.00 07/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208618813
Principal investigator 1 Alkermes, Inc. $2,984.85 07/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208619037
Principal investigator 1 Alkermes, Inc. $2,835.00 07/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208621296
Principal investigator 1 Alkermes, Inc. $2,870.10 07/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208621708
Principal investigator 1 Alkermes, Inc. $2,870.10 07/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208622387
Principal investigator 1 Alkermes, Inc. $2,910.60 07/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208622583
Principal investigator 1 Alkermes, Inc. $2,835.00 07/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208622789
Principal investigator 1 Alkermes, Inc. $3,005.78 07/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208623038
Principal investigator 1 Alkermes, Inc. $2,984.85 07/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208624610
Principal investigator 1 Alkermes, Inc. $2,632.50 07/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208624846
Principal investigator 1 Alkermes, Inc. $3,025.35 07/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208625525
Principal investigator 1 Alkermes, Inc. $2,263.95 07/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208626778
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,681.00 07/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242355128
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,681.00 07/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242355130
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,024.00 07/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242355132
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,714.00 07/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242355134
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,714.00 07/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242355136
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $77.00 07/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242355138
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $54.00 07/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242355140
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,056.00 07/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242353975
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,056.00 07/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242353977
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,354.00 07/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242353979
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,211.00 07/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242353981
Principal investigator 1 Alkermes, Inc. $4,166.10 06/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208615369
Principal investigator 1 Alkermes, Inc. $2,835.00 06/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208615543
Principal investigator 1 Alkermes, Inc. $4,094.55 06/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208618441
Principal investigator 1 Alkermes, Inc. $4,166.10 06/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208618901
Principal investigator 1 Alkermes, Inc. $2,835.00 06/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208619639
Principal investigator 1 Alkermes, Inc. $2,835.00 06/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208622653
Principal investigator 1 Alkermes, Inc. $2,835.00 06/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208623128
Principal investigator 1 Alkermes, Inc. $2,835.00 06/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208625373
Principal investigator 1 Alkermes, Inc. $2,984.85 06/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208613029
Principal investigator 1 Alkermes, Inc. $2,632.50 06/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208613233
Principal investigator 1 Alkermes, Inc. $2,984.85 06/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208613235
Principal investigator 1 Alkermes, Inc. $2,910.60 06/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208613659
Principal investigator 1 Alkermes, Inc. $2,910.60 06/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208614338
Principal investigator 1 Alkermes, Inc. $2,984.85 06/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208615559
Principal investigator 1 Alkermes, Inc. $2,984.85 06/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208615807
Principal investigator 1 Alkermes, Inc. $2,984.85 06/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208619155
Principal investigator 1 Alkermes, Inc. $2,910.60 06/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208620758
Principal investigator 1 Alkermes, Inc. $2,632.50 06/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208621388
Principal investigator 1 Alkermes, Inc. $2,632.50 06/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208622896
Principal investigator 1 Alkermes, Inc. $2,870.10 06/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208624496
Principal investigator 1 Alkermes, Inc. $2,632.50 06/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208626246
Principal investigator 1 Alkermes, Inc. $2,910.60 06/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208626646
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,211.00 06/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242351506
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,212.00 06/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242351508
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,354.00 06/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242351510
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,703.00 06/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242351512
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,244.00 06/11/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242350130
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,461.00 06/11/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242350132
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,461.00 06/11/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242350134
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,909.00 06/11/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242350140
Principal investigator 1 Alkermes, Inc. $2,835.00 05/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208615375
Principal investigator 1 Alkermes, Inc. $2,835.00 05/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208622027
Principal investigator 1 Alkermes, Inc. $2,835.00 05/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208623134
Principal investigator 1 Alkermes, Inc. $2,835.00 05/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208624488
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,017.00 05/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242347730
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,354.00 05/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242347732
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,211.00 05/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242347734
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,125.00 05/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242347736
Principal investigator 1 Alkermes, Inc. $2,870.10 05/16/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208613229
Principal investigator 1 Alkermes, Inc. $2,984.85 05/16/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208613439
Principal investigator 1 Alkermes, Inc. $2,910.60 05/16/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208614110
Principal investigator 1 Alkermes, Inc. $2,632.50 05/16/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208614543
Principal investigator 1 Alkermes, Inc. $2,910.60 05/16/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208615795
Principal investigator 1 Alkermes, Inc. $2,984.85 05/16/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208619863
Principal investigator 1 Alkermes, Inc. $2,984.85 05/16/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208619865
Principal investigator 1 Alkermes, Inc. $2,632.50 05/16/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208622655
Principal investigator 1 Alkermes, Inc. $2,984.85 05/16/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208622657
Principal investigator 1 Alkermes, Inc. $2,189.70 05/16/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208624258
Principal investigator 1 Alkermes, Inc. $2,984.85 05/16/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208624486
Principal investigator 1 Alkermes, Inc. $2,632.50 05/16/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208626870
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,269.00 05/07/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242347250
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,269.00 05/07/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242347252
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,269.00 05/07/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242347254
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,883.00 05/07/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242347256
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,461.00 05/07/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242347258
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,461.00 05/07/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242347260
Principal investigator 1 Alkermes, Inc. $2,835.00 04/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208615867
Principal investigator 1 Alkermes, Inc. $3,005.78 04/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208616071
Principal investigator 1 Alkermes, Inc. $2,835.00 04/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208621885
Principal investigator 1 Alkermes, Inc. $2,835.00 04/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208624544
Principal investigator 1 Alkermes, Inc. $2,835.00 04/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208625668
Principal investigator 1 Alkermes, Inc. $3,005.78 04/23/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208626066
Principal investigator 1 Alkermes, Inc. $2,984.85 04/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208614821
Principal investigator 1 Alkermes, Inc. $2,189.70 04/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208616541
Principal investigator 1 Alkermes, Inc. $2,870.10 04/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208618511
Principal investigator 1 Alkermes, Inc. $2,984.85 04/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208620155
Principal investigator 1 Alkermes, Inc. $2,870.10 04/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208620818
Principal investigator 1 Alkermes, Inc. $3,199.50 04/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208624086
Principal investigator 1 Alkermes, Inc. $2,984.85 04/21/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208626692
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,269.00 04/04/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242339329
Principal investigator 1 Alkermes, Inc. $3,005.78 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208613445
Principal investigator 1 Alkermes, Inc. $2,835.00 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208614342
Principal investigator 1 Alkermes, Inc. $3,199.50 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208614370
Principal investigator 1 Alkermes, Inc. $3,469.50 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208615813
Principal investigator 1 Alkermes, Inc. $2,984.85 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208616713
Principal investigator 1 Alkermes, Inc. $3,469.50 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208617939
Principal investigator 1 Alkermes, Inc. $2,189.70 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208618247
Principal investigator 1 Alkermes, Inc. $2,870.10 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208618947
Principal investigator 1 Alkermes, Inc. $2,835.00 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208620113
Principal investigator 1 Alkermes, Inc. $3,005.78 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208622033
Principal investigator 1 Alkermes, Inc. $3,005.78 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208622900
Principal investigator 1 Alkermes, Inc. $2,835.00 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208623144
Principal investigator 1 Alkermes, Inc. $2,189.70 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208623854
Principal investigator 1 Alkermes, Inc. $2,870.10 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208624957
Principal investigator 1 Alkermes, Inc. $2,835.00 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208625864
Principal investigator 1 Alkermes, Inc. $3,005.78 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208626028
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,212.00 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242339009
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,354.00 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242339011
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,703.00 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242339013
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,056.00 04/02/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242339015
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,500.00 03/14/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242337983
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,500.00 03/14/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242337985
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,500.00 03/14/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242337987
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $650.00 03/14/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242337989
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $12,825.00 03/14/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242337991
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $750.00 03/14/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242337993
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,100.00 03/14/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-601 No dispute reported 06/30/2026 1242338023
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $750.00 03/12/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242336589
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,100.00 03/12/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242337727
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,500.00 03/12/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242337729
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,500.00 03/12/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242337731
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $12,825.00 03/12/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242337791
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,500.00 03/12/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242337793
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $650.00 03/12/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-321 No dispute reported 06/30/2026 1242337795
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,909.00 03/10/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242334864
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,975.00 03/10/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242334866
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,461.00 02/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242333168
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,461.00 02/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242333170
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,883.00 02/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242333172
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,244.00 02/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242333174
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,461.00 02/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242333176
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,461.00 02/25/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242333178
Principal investigator 1 Alkermes, Inc. $4,166.10 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208614112
Principal investigator 1 Alkermes, Inc. $1,981.80 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208614114
Principal investigator 1 Alkermes, Inc. $2,835.00 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208614336
Principal investigator 1 Alkermes, Inc. $4,166.10 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208614777
Principal investigator 1 Alkermes, Inc. $3,025.35 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208614779
Principal investigator 1 Alkermes, Inc. $2,835.00 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208615193
Principal investigator 1 Alkermes, Inc. $3,199.50 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208615551
Principal investigator 1 Alkermes, Inc. $4,166.10 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208615801
Principal investigator 1 Alkermes, Inc. $4,166.10 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208617109
Principal investigator 1 Alkermes, Inc. $2,870.10 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208617927
Principal investigator 1 Alkermes, Inc. $4,166.10 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208618191
Principal investigator 1 Alkermes, Inc. $4,166.10 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208618443
Principal investigator 1 Alkermes, Inc. $2,870.10 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208619381
Principal investigator 1 Alkermes, Inc. $4,166.10 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208620317
Principal investigator 1 Alkermes, Inc. $1,981.80 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208621594
Principal investigator 1 Alkermes, Inc. $2,835.00 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208622483
Principal investigator 1 Alkermes, Inc. $3,199.50 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208622888
Principal investigator 1 Alkermes, Inc. $1,981.80 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208623608
Principal investigator 1 Alkermes, Inc. $3,025.35 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208624288
Principal investigator 1 Alkermes, Inc. $2,870.10 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208625139
Principal investigator 1 Alkermes, Inc. $1,981.80 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208625143
Principal investigator 1 Alkermes, Inc. $4,166.10 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208625619
Principal investigator 1 Alkermes, Inc. $3,025.35 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208626022
Principal investigator 1 Alkermes, Inc. $2,835.00 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208626422
Principal investigator 1 Alkermes, Inc. $2,870.10 02/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208626886
Principal investigator 1 Alkermes, Inc. $106,298.50 01/28/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208612843
Principal investigator 1 Alkermes, Inc. $66,766.00 01/27/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208612821
Principal investigator 1 Alkermes, Inc. $2,870.10 01/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208613846
Principal investigator 1 Alkermes, Inc. $2,870.10 01/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208614521
Principal investigator 1 Alkermes, Inc. $2,910.60 01/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208615997
Principal investigator 1 Alkermes, Inc. $2,870.10 01/24/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208623788
Principal investigator 1 Alkermes, Inc. $2,835.00 01/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208613017
Principal investigator 1 Alkermes, Inc. $3,025.35 01/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208613435
Principal investigator 1 Alkermes, Inc. $3,025.35 01/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208614092
Principal investigator 1 Alkermes, Inc. $2,835.00 01/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208614104
Principal investigator 1 Alkermes, Inc. $3,025.35 01/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208614983
Principal investigator 1 Alkermes, Inc. $2,835.00 01/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208616873
Principal investigator 1 Alkermes, Inc. $1,981.80 01/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208617491
Principal investigator 1 Alkermes, Inc. $1,981.80 01/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208618175
Principal investigator 1 Alkermes, Inc. $1,981.80 01/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208618895
Principal investigator 1 Alkermes, Inc. $2,263.95 01/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208622463
Principal investigator 1 Alkermes, Inc. $2,835.00 01/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208623124
Principal investigator 1 Alkermes, Inc. $2,835.00 01/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208624480
Principal investigator 1 Alkermes, Inc. $1,981.80 01/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208625123
Principal investigator 1 Alkermes, Inc. $2,835.00 01/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208626232
Principal investigator 1 Alkermes, Inc. $1,981.80 01/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208626878
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,269.00 01/13/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242328613
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,269.00 01/13/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
ITI-007-421 No dispute reported 06/30/2026 1242328615
Principal investigator 1 Alkermes, Inc. $17,156.90 01/01/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) No dispute reported 06/30/2026 1208627007
Principal investigator 1 Alkermes, Inc. $19,633.04 01/01/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES, LLC
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1208627039